Vivozon publishes clinical results of oral drug addiction treatment candidate '해시 게임 바카라2471' in international academic journal

[by Ji, Yong Jun] Vivozon announced on April 24 that the results of the Phase 1 clinical trial for ‘해시 게임 바카라2471 (development code)’, being developed as an oral treatment for pain and drug addiction, have been published in the latest issue of the international academic journal ‘CNS Drugs.’ The journal is a Science Citation Index Expanded (SCIE)-listed medical journal specializing in the central nervous system (CNS) field, with an impact factor (IF) of 7.4.

The published paper presents the results of single- and repeated-dose Phase 1 clinical trials of 해시 게임 바카라2471, conducted at the Clinical Trial Center of Seoul National University Bundang Hospital. The study evaluated the following aspects: the safety and tolerability of orally administered 해시 게임 바카라2471, its pharmacokinetic properties based on dosage, the impact of administration on food intake, and its effect on the desire to smoke.

As a result, 해시 게임 바카라2471 demonstrated safety and tolerability even at high doses exceeding the anticipated therapeutic range, and dose-dependent pharmacodynamic properties were observed. Furthermore, an exploratory assessment of ‘smoking desire’ conducted on smokers confirmed a reduction in the urge to smoke, thereby supporting the potential as a treatment for addiction.

In June 2024, the company secured approval for a phase 2 clinical trial plan (IND) for the oral formulation of 해시 게임 바카라2471 targeting patients with postherpetic neuralgia and is currently conducting the trial at three Korean institutions. The company aims to widely use the drug for pain management in the future along with ‘Unafra (opioid analgesic) injection,’ Korea’s 38th novel drug approved by the Ministry of Food and Drug Safety in December of last year. Additionally, preparations are underway for Phase 2 clinical trials in the United States to develop the oral 해시 게임 바카라2471 as a treatment for drug addiction in response to the country’s ongoing opioid misuse and addiction crisis.

해시 게임 바카라2471, Vivozon’s second pipeline, is a first-in-class drug candidate discovered through the company’s multi-target new drug development platform, similar to Opiranserin (해시 게임 바카라149). It exerts a dual antagonistic mechanism by simultaneously inhibiting ‘mGluR5’ and ‘5-HT2AR,’ two receptors that are associated with the transmission of addiction and pain signals.

“The publication of 해시 게임 바카라2471’s clinical trial results in a prestigious international academic journal is significant, as it represents international recognition of the potential for developing an oral treatment for drug addiction,” a Vivozon official said. “We will continue to make every effort to improve patients’ ‘quality of life’ through the development of innovative new drugs based on scientific evidence.”